A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab

Study Overview
=================
Brief Summary
-----------------
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab.

Detailed Description
-----------------
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after administration of Fexuclue Tab. Subjects who met the inclusion/exclusion criteria will administer Fexuclue Tablet once a day for four weeks after registration, regardless of their meals. If esophagitis is not treated or symptoms continue after 4 weeks of administration, the subject will continue to administer Fexuclue Tablet for 4 more weeks (maximum administration period: 8 weeks).

Official Title
-----------------
A Multi-Center, Prospective, Observational Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab. in Patients With Erosive Gastroesophageal Reflux Disease

Conditions
-----------------
Gastroesophageal Reflux Disease

Intervention / Treatment
-----------------
* Drug: Fexuprazan Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult men and women aged 19 to 75 years of age at the time of registration. A patient with erosive gastroesophageal reflux disease who is scheduled to administer Fexuclue Tab. for the first time based on the medical judgement of the researcher based on the medication authorization. A person who voluntarily agrees to participate in this observation study and signed the informed consent form. Exclusion Criteria: A person who falls under the prohibition of administration according to the permission for Fexuclue Tablet Patients with hypersensitivity to the components of Fexuclue tablet or Fexuclue tablet and a history thereof Patients undergoing Atazanavir, Nelfinavir or Lilpivirin-containing preparations Pregnant and lactating women Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabortion A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices; In addition to the above, a person who has determined that the researcher (the doctor in charge) is not suitable for participation in this observation study

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Treatment group<br>patients with gastroesophageal reflux disease | Drug: Fexuprazan Hydrochloride<br>* Fexuclue Tablet 40mg<br>* Other names: Fexuclue Tablet;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average score change | in Reflux Disease Questionnaire | at 4 weeks (up to 8 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average score change | individual score in Reflux Disease Questionnaire | at 4 weeks (up to 8 weeks) |